Chronic Lymphocytic Leukemia | Specialty

Dr. Choi on Impact of Frontline Treatment Decisions on Relapsed/Refractory CLL

April 3rd 2020

Michael Choi, MD, discusses how up-front treatment decisions impact what options can be given in the relapsed/refractory setting for patients with chronic lymphocytic leukemia.

Dr. Awan on Novel Strategies Under Exploration in Relapsed/Refractory CLL

April 2nd 2020

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum

March 20th 2020

Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.

Investigators Pursue Less-Toxic Treatment in Frontline CLL

March 16th 2020

Investigators are evaluating whether the addition of venetoclax to a standard doublet regimen in chronic lymphocytic leukemia can induce responses deep enough to allow patients to not only suspend long-term treatment but also avoid associated toxicity.

Optimizing Frontline Therapy With Cost-Savings Considerations in CLL

March 12th 2020

Matthew S. Davids, MD, MMSc, discusses data that were presented with novel combinations in chronic lymphocytic leukemia at the 2019 ASH Annual Meeting and the importance of conducting cost-effective analyses.

Frontline Venetoclax/Obinutuzumab Approved in Europe in CLL

March 12th 2020

The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Dr. Raphael on the CLARITY Trial in CLL

March 10th 2020

Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the phase II CLARITY trial in chronic lymphocytic leukemia (CLL).

Dr. Woyach on Treatment Challenges in CLL

March 7th 2020

Jennifer Woyach, MD, discusses current challenges in chronic lymphocytic leukemia treatment.

Dr. Awan on Utilizing Acalabrutinib in CLL

March 6th 2020

Farrukh Awan, MD, discusses the utilization of acalabrutinib in patients with chronic lymphocytic leukemia.

CLL Treatment Paradigm Expands Toward Novel Combo Regimens

March 6th 2020

Bruce G. Raphael, MD, discusses recent pivotal trials in chronic lymphocytic leukemia and the utility of triplet regimens for older patients.

Dr. Choi on Frontline Treatment Considerations in CLL

March 4th 2020

Michael Choi, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Dr. Pagel on Time-Limited Therapy in CLL

March 4th 2020

John M. Pagel, MD, PhD, discusses time-limited therapy in chronic lymphocytic leukemia.

Dr. Raphael on the Treatment Landscape of CLL

March 3rd 2020

Bruce G. Raphael, MD, discusses the treatment landscape of chronic lymphocytic leukemia.

CLL Treatment in Community Oncology

February 29th 2020

Sequencing Therapy in CLL: BTK and BCL2 Inhibitors

February 29th 2020

BTK Inhibitors in CLL: Treatment Selection

February 29th 2020

Second-Generation BTK Data in CLL

February 29th 2020

Evolution of BTK Inhibitors in CLL

February 29th 2020

BTK and BCL-2 Inhibitors Reach New Milestones in CLL

February 26th 2020

Michael Choi, MD, sheds light on the data with BTK and BCL-2 inhibitors in CLL and shares ongoing research being done with PI3K inhibitors and CAR T-cell therapy in the relapsed/refractory setting.

Dr. Danilov on ELEVATE-TN Trial Results in CLL

February 21st 2020

Alexey V. Danilov, MD, PhD, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia.